# Amyloid accumulation, brain atrophy, and cognitive decline in emergent Alzheimer's disease

**Authors:** Ying Xia, Pierrick Bourgeat, Vincent Doré, Jurgen Fripp, Yen Ying Lim, Simon M. Laws, Christopher Fowler, Christopher C. Rowe, Colin L. Masters, Elizabeth J. Coulson, Paul Maruff

PMC · DOI: 10.1002/dad2.70155 · 2025-07-29

## TL;DR

This study explores early Alzheimer's disease in cognitively healthy individuals, finding that amyloid buildup is linked to memory decline but not brain shrinkage.

## Contribution

The study identifies early Alzheimer's markers in cognitively unimpaired individuals, linking amyloid accumulation to memory loss without structural brain changes.

## Key findings

- Emergent Alzheimer's is associated with increased amyloid-β accumulation and subtle memory decline.
- No significant brain atrophy in the basal forebrain or hippocampus was observed in early Alzheimer's.
- Amyloid accumulation may impair cognition before structural brain changes occur.

## Abstract

Emergent Alzheimer's disease (AD) represents a transitional stage where cognitively unimpaired (CU) individuals exhibit subthreshold but increasing amyloid‐β (Aβ) levels. The impact of Aβ accumulation on brain volume loss and cognition during this early stage remains unclear.

This retrospective cohort study analyzed data from 408 CU participants who were initially Aβ− (< 15 Centiloids) and followed for up to 15 years. Changes in basal forebrain and hippocampal volume, along with domain‐specific cognitive performance, were compared between those who progressed to Aβ+ (≥20 Centiloids) and those who remained Aβ−.

Sixty‐five CU participants progressed to Aβ+, indicating emergent AD, and showed faster Aβ accumulation and subtle memory decline. However, no significant differences in rate of BF and hippocampal atrophy were observed between groups.

The results suggest that during this emergent phase of AD, Aβ accumulation is associated with episodic memory loss, in the absence of detectable accelerated brain atrophy.

Identified cognitively unimpaired individuals in the emergent stage of Alzheimer's disease (AD).Emergent AD exhibits a greater rate of amyloid‐β (Aβ) accumulation.No accelerated volume loss detected in the basal forebrain or hippocampus.Emergent AD is also associated with a subtle decline in memory.Early Aβ accumulation may impair cognitive function before structural atrophy.

Identified cognitively unimpaired individuals in the emergent stage of Alzheimer's disease (AD).

Emergent AD exhibits a greater rate of amyloid‐β (Aβ) accumulation.

No accelerated volume loss detected in the basal forebrain or hippocampus.

Emergent AD is also associated with a subtle decline in memory.

Early Aβ accumulation may impair cognitive function before structural atrophy.

## Linked entities

- **Diseases:** Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, SUCO (SUN domain containing ossification factor) [NCBI Gene 51430] {aka C1orf9, CH1, OPT, SLP1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** stroke (MESH:D020521), diabetes (MESH:D003920), schizophrenia (MESH:D012559), decline in memory and attention (MESH:D001289), head injury (MESH:D006259), bipolar disorder (MESH:D001714), dysfunction (MESH:D006331), impaired learning (MESH:D007859), brain volume loss (MESH:D001927), Volume loss (MESH:D016388), Parkinson disease (MESH:D010300), AD (MESH:D000544), CU (MESH:D003072), neuronal dysfunction (MESH:D009461), cholinergic (MESH:C535672), neurodegenerative (MESH:D019636), Dementia (MESH:D003704), Depression (MESH:D003866), Memory decline (MESH:D060825), neuronal (MESH:D009410), neuroinflammation (MESH:D000090862), amyloid (MESH:C000718787), AIBL (MESH:C564543), atrophy (MESH:D001284), brain atrophy (MESH:C566985), LMMs (MESH:D004195), episodic memory loss (MESH:D008569), RESEARCH-IN-CONTEXT (MESH:D014947), obstructive sleep apnea (MESH:D020181), cardiovascular and cerebrovascular diseases (MESH:D002318), hypertension (MESH:D006973), structural degeneration (MESH:D020914)
- **Chemicals:** 18F-flutemetamol (MESH:C581552), alcohol (MESH:D000438), scopolamine (MESH:D012601), 11C-Pittsburgh compound-B (-), 18F-florbetapir (MESH:C545186)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12305117/full.md

---
Source: https://tomesphere.com/paper/PMC12305117